Heron Pharma showcases expertise at CPhI China 2020
Dec. 16-18, 2020, CPhI China 2020 was ceremoniously held in Shanghai. There are totally eight CPHI exhibitions worldwide, however, only China’s exhibition was held this year affected by the COVID-19. It shows the reliability of China's pharmaceutical industry and supply chain under the epidemic situation. Heron pharma closely follows China's progress in pharmaceutical industry from big to a powerful, and brings better service and more competitive products to global customers.
Nanjing Heron Pharmaceutical Science and Technology Co., Ltd. is committed to the development of full range of Vitamin D derivatives, providing high-quality of FDFs, APIs, intermediates and impurities. Several APIs have been registered in China and overseas. The featured products like Alfacalcidol, calcitriol and eldecalcitol were promoted on the booth attracted many customers.
Heron (Shanghai) Pharmaceutical Science and Technology Co., Ltd., a holding subsidiary of Nanjing Heron Pharma, is committed to provide high-quality of products and regulations, technical services globally and also served China’s pharmaceutical and veterinary industry. Heron (Shanghai) is the exclusive distributor for Nippon Nikko Group in China Mainland’s excipients market. Medium-chain triglycerides and ceteth-20, IPM will be registered in China 2021, in which many enterprises are interested in cooperation.
Post time: Dec-22-2020